

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/12924593>

Negative Regulation of Transactivation Function but Not DNA Binding of NF- κ B and AP-1 by I κ B1 in Breast Cancer Cells

Article in *Journal of Biological Chemistry* · July 1999

DOI: 10.1074/jbc.274.26.18827 · Source: PubMed

CITATIONS

59

READS

7

6 authors, including:



Harikrishna Nakshatri

Indiana University School of Medicine

253 PUBLICATIONS 11,928 CITATIONS

SEE PROFILE

Negative Regulation of Transactivation Function but Not DNA Binding of NF- κ B and AP-1 by I κ B β 1 in Breast Cancer Cells*

(Received for publication, December 10, 1998, and in revised form, April 8, 1999)

Thomas R. Newton^{‡§}, Nikhil M. Patel^{‡§}, Poornima Bhat-Nakshatri[¶], Carmen R. Stauss[‡],
Robert J. Goulet, Jr.[‡], and Harikrishna Nakshatri^{‡¶**‡‡}

From the Departments of [‡]Surgery, [¶]Medicine, ^{||}Biochemistry and Molecular Biology, and ^{**}Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana 46202

The transcription factor NF- κ B regulates the expression of genes involved in cancer cell invasion, metastasis, angiogenesis, and resistance to chemotherapy. In normal cells NF- κ B is maintained in the cytoplasm by protein-protein interaction with inhibitor I κ Bs. In contrast, in cancer cells a substantial amount of NF- κ B is in the nucleus and constitutively activates target genes. To understand the mechanisms of constitutive NF- κ B activation, we have analyzed the function of I κ B α and I κ B β in breast cancer cells. In most cases, constitutive NF- κ B DNA binding correlated with reduced levels of either I κ B α or I κ B β isoforms. Overexpression of I κ B α but not I κ B β 1 resulted in reduced constitutive DNA binding of NF- κ B in MDA-MB-231 cells. Unexpectedly, I κ B β 1 overexpression moderately increased 12-*O*-tetradecanoylphorbol-13-acetate- and interleukin-1-inducible NF- κ B DNA binding. 12-*O*-Tetradecanoylphorbol-13-acetate- and interleukin-1-induced transactivation by NF- κ B, however, was lower in I κ B β 1-overexpressing cells. Mutants of I κ B β 1 lacking the C-terminal casein kinase II phosphorylation sites, which form a stable complex with DNA bound NF- κ B without inhibiting its transactivation in other cell types, repressed the transactivation by NF- κ B in MDA-MB-231 cells. Consistent with the results of transient transfections, the expression of urokinase plasminogen activator, an NF- κ B target gene, was reduced in I κ B β 1-overexpressing cells. These results suggest that depending on the cell type, I κ B β 1 represses the expression of NF- κ B-regulated genes by inhibiting either DNA binding or transactivation function of NF- κ B.

Regulation of gene expression by the NF- κ B/Rel family of transcription factors is controlled mainly by the inhibitory I κ B proteins which include I κ B α , I κ B β , I κ B γ , and I κ B ϵ (1–4). The active complex of NF- κ B is composed of homodimers and heterodimers of p50, RelA, RelB, and c-Rel. These complexes are sequestered in the cytoplasm by I κ Bs. Extracellular signal-induced phosphorylation and subsequent degradation of I κ Bs

is essential for nuclear translocation of NF- κ B. NF- κ B binds to the recognition elements in the promoter region of target genes and activates transcription. Transactivation by NF- κ B involves interaction with transcriptional coactivators such as CBP/p300 and SRC-1 and general transcription factors including TBP (5–8). In addition, NF- κ B interacts with transcription factors such as activator protein 1 (AP-1) and serum response factors and synergistically activates transcription (9, 10).

I κ B proteins determine the duration of transactivation by NF- κ B. I κ B α is involved in transient activation of NF- κ B because it is degraded rapidly upon stimulation and is resynthesized by activated NF- κ B (1–4). Most of the inducers of NF- κ B cause degradation of I κ B α . The newly synthesized I κ B α sequesters NF- κ B in the cytoplasm and terminates the signal. I κ B β is involved in persistent activation of NF- κ B (11). Degradation of I κ B β is much more delayed than I κ B α and resynthesis is independent of NF- κ B (11). Degradation of I κ B β is dependent on the cell type and the extracellular signals that induce NF- κ B. For example, whereas interleukin 1 (IL-1) induces degradation of I κ B β in most cell types tested, tumor necrosis factor (TNF- α) induces degradation of I κ B β in E29.1 T cell hybridomas but not in Jurkat cells (11, 12). Together, but not separately, TNF- α and interferon γ induce degradation of I κ B β in PC12 cells (13). The ability of I κ B β to repress NF- κ B DNA binding is determined by the basal phosphorylation of the C-terminal PEST domain (14). The newly synthesized hypophosphorylated I κ B β functions as a chaperone for NF- κ B by protecting it from I κ B α (15). The I κ B β -NF- κ B complex enters the nucleus, binds to DNA, and activates transcription (16, 17). The phosphorylation of the PEST domain by casein kinase II or the association of the I κ B β -NF- κ B complex with high mobility group I (HMG I) proteins on selected promoters converts I κ B β to a repressor of NF- κ B DNA binding activity (14, 17).

Two isoforms of I κ B β , β 1 and β 2, have been described recently (18). These isoforms differ in their C-terminal amino acids. I κ B β 1 is functionally similar to I κ B α and efficiently represses the activity of p50:RelA heterodimers. It is found in both the nucleus and cytoplasm and is degraded by various stimuli. In contrast, I κ B β 2 is a cytoplasmic protein that is refractory to signal-induced degradation. Although both isoforms are indistinguishable in their binding preferences to cellular NF- κ B/Rel homo- and heterodimers, I κ B β 2 is more effective in inhibiting RelA homodimers than p50:RelA and p50:c-Rel heterodimers (18). This property of I κ B β 2 is similar to that of I κ B ϵ which preferentially inhibits the activity of RelA homodimers (19).

There is increasing evidence for the role of NF- κ B in cancer progression and resistance to chemotherapy (20, 21). Constitutive activation of NF- κ B has been observed in Hodgkin's lymphoma, melanomas, juvenile myelomonocytic leukemia, cuta-

* This work was supported by the RGK Foundation and the Gustavus and Louise Pfeiffer Research Foundation (to H. N.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Both authors contributed equally to this work.

‡‡ To whom correspondence should be addressed: R4-202, Indiana Cancer Research Institute, 1044 W. Walnut St., Indianapolis, IN 46202. Tel.: 317-278-2238; Fax: 317-274-0396; E-mail: hnakshat@iupui.edu.

¹ The abbreviations used are: NF- κ B, nuclear factor κ B; AP-1, activator protein 1; I κ B, inhibitor κ B; IL-1, interleukin 1; TPA, 12-*O*-tetradecanoylphorbol-13-acetate; uPA, urokinase plasminogen activator; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay; MEM, minimum Eagle's medium; EGF, epidermal growth factor; HMG I, high mobility group I; ER α , estrogen receptor α .




FIG. 1. Differential expression of I κ B α , I κ B β 1, and I κ B β 2 in breast cancer cells. A, DNA binding activity of NF- κ B in breast cancer cell lines. Whole cell extracts (6 μ g) were incubated with double-stranded oligonucleotide containing NF- κ B, SP1, or CTF/NF-1-binding

neous T cell lymphoma, and human T cell leukemia virus type I Tax protein-mediated cellular transformation (22–26). We and others (27, 28) have shown that NF- κ B is constitutively active in a subset of breast cancers. In this study, we have investigated the role of I κ B α and I κ B β in constitutive activation of NF- κ B in breast cancer cells. Constitutive DNA binding correlated with reduced levels of either I κ B α or I κ B β . Both isoforms of I κ B β are present in breast cancer cell lines and primary breast cancers. Overexpressed I κ B α but not I κ B β 1 repressed constitutive DNA binding of NF- κ B in MDA-MB-231 cells. I κ B β 1, in contrast, repressed transactivation by NF- κ B. Unlike in the mouse embryonal carcinoma cell line P19 and the human embryonic kidney cell line 293, mutants of I κ B β 1 that cannot be phosphorylated by casein kinase II efficiently repressed transactivation by NF- κ B in MDA-MB-231 cells (17, 29). Taken together, these results reveal a novel cell type-specific inhibitory regulation of transactivation function but not DNA binding of NF- κ B by I κ B β 1.

EXPERIMENTAL PROCEDURES

Cell Culture—All breast cancer cell lines were purchased from ATCC, and their growth conditions have been described previously (30). 10^{-9} M insulin was added to MDA-MB-231 and its clones during long term culturing.

Recombinant Plasmids—NF- κ B/CAT reporter gene, human I κ B α , and mouse I κ B β expression vectors have been described previously (27). The AP-1/CAT reporter was a generous gift of E. O'Neill (Merck) and contains three copies of an AP-1 site from the human metallothionein gene (31). Human I κ B β and its mutants were generous gifts from D. Ballard (Vanderbilt University, Nashville, TN) and were described previously (29). mI κ B β 1 Δ C, which lacks 50 amino acids at the C-terminal, was generated by cloning a *NotI*-*HindIII* fragment of mI κ B β 1 to the pcDNA3 expression vector (Invitrogen). Retrovirus constructs containing hI κ B α and mI κ B β 1 coding sequences were prepared by cloning cDNAs into the respective *EcoRI* and *NotI* sites of the modified retrovirus vector LxSN (32).

Retrovirus Preparation and Transduction—LxSN vectors were amphotropically packaged into the AM12 packaging cell line (33), and the cell-free supernatant was used to transduce MDA-MB-231 cells as described previously (34). Vector containing clones were isolated by growing cells in G418 (1 mg/ml).

Electrophoretic Mobility Shift Assay (EMSA)—Whole cell extracts from cells were prepared and subjected to EMSA as described previously (27). Densitometric analysis was performed to classify constitutive DNA binding activity.

Western Blotting—Cell extracts were prepared in radioimmunoprecipitation assay buffer (35) and subjected to Western blotting as recommended by the antibody manufacturers (Santa Cruz Biotechnology and Sigma). For quantitation, autoradiograms were scanned using a densitometer.

DNA Immunoprecipitation—Nuclear extracts were prepared as described previously (36). Nuclear extracts supplemented with 1% Nonidet P-40 were precleared in insoluble protein A solution (Sigma) and subjected to EMSA reaction. Antibodies (0.2 μ g) were added, and incubation was carried out for 1 h on ice. Protein A-agarose (20- μ l bead volume) was added, and the reaction mixture was incubated for 1 h at 4 °C with gentle rocking. Protein A-agarose was collected by centrifugation, washed five times in 1 \times EMSA buffer (10 mM Tris-HCl, 0.5 mM EDTA, 100 mM KCl, 10% glycerol, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and 0.2% Nonidet P-40), and subjected to SDS-polyacrylamide gel electrophoresis. The amount of radioactive DNA immunoprecipitated with the antibody complex was visualized by autoradiography and quantitated by densitometric scanning.

Transient Transfections and CAT Assays—Transient transfections and the CAT assay have been described previously (27). Statistical analysis was performed using Statview software (version 4.1; Abacus

sites and subjected to EMSA. CTF/NF-1 displays multiple bands due to alternative splicing. B, RelA and I κ B expression in breast cancer cell lines. Whole cell extracts (50 μ g) from indicated cell lines were analyzed for RelA, p105/p50, and I κ Bs by Western blotting. For identification of I κ B β 1, an antibody raised against the unique C-terminal region of I κ B β 1 was used in Western blotting. Integrity of proteins in each lanes was verified by probing the blot with antibody against α -tubulin.

TABLE I
Summary of NF- κ B DNA binding activity and I κ B expression in breast cancer cell lines

ER α status in these cell lines has been described previously (30, 37). A value of 4+ is assigned to the most intense signal among various cell lines.

	ER α	NF- κ B	I κ B α	I κ B β 1	I κ B β 2
MCF-7	+	+	++++	+	+++
T47-D	+	+	++++	++	+++
ZR-75	+	++	++	++	+++
MDA-MB-231	-	+++	++	+	+
MDA-MB-435	-	+++	+	++	++++
MDA-MB-157	-	+	+++	++	+++
MDA-MB-436	-	++++	+++	+++	+
MDA-MB-468	-	+++	+	++++	++++
SK-BR-3	-	++	++++	++	+++
Hs578T	-	++	+	++	+
HBL100	-	++++	++++	+++	+++

Concepts, Berkeley, CA). Data were evaluated by one-factor analysis of variance and Fisher's protected least significant difference as a post hoc test.

Serum and Epidermal Growth Factor (EGF) Treatment and Northern Blotting—For serum stimulation, cells were maintained in MEM without serum for 48 h. MEM with 10% fetal calf serum was added, and the cells were harvested after 4 h. For EGF treatment, cells were maintained in MEM (without fetal calf serum) for 48 h. EGF (30 ng/ml) was added, and cells were harvested after 4 h. RNA was prepared by the guanidinium isothiocyanate/cesium chloride method and subjected to Northern blotting as described previously (30).

RESULTS

Differential Expression of I κ Bs in Breast Cancer Cells—Constitutive NF- κ B DNA binding activity in several breast cancer cell lines was compared with the expression level of I κ B α and I κ B β (Fig. 1 and Table I). MCF-7, T47-D, and MDA-MB-157 cells displayed the least amount of NF- κ B DNA binding and higher levels of I κ B α and I κ B β compared with other cell lines (see "Experimental Procedures"). In comparison, NF- κ B DNA binding activity in other cell lines were either high (MDA-MB-231, MDA-MB-435, MDA-MB-436, MDA-MB-468, and HBL-100) or intermediate (ZR-75-1, SK-BR-3, and Hs578T) (Fig. 1A and Table I). Among these cell lines, MCF-7, T47-D, and ZR-75-1 express estrogen receptor α (ER α) and are more differentiated than other cell lines (37). Most of the cell lines that displayed elevated NF- κ B DNA binding activity are ER α -negative, consistent with our previous report (27). In contrast to NF- κ B, DNA binding of SP1 and CTF/NF-1 family transcription factors did not correlate with ER α status (Fig. 1A). The NF- κ B complex is a heterodimer of RelA and p50 subunits as determined by antibody supershift assays (data not shown). In general, NF- κ B DNA binding activity correlated inversely with the levels of I κ B α , I κ B β 1, and I κ B β 2 (Fig. 1B, Table I). For example, higher NF- κ B DNA binding correlated with reduced levels of either I κ B α (MDA-MB-435 and MDA-MB-468), I κ B β 2 (MDA-MB-436) or I κ B α , or I κ B β 1 and I κ B β 2 (MDA-MB-231). I κ B β 2 is the major I κ B β in breast cancer cell lines with the exception of HBL-100 and MDA-MB-436 cells which contained similar levels of I κ B β 1 and I κ B β 2. Reverse transcription-polymerase chain reaction was used to confirm the presence of transcripts corresponding to I κ B β 1 and I κ B β 2 in breast cancer cells (data not shown). Proteins corresponding to I κ B β 1 and I κ B β 2 were also observed in primary breast cancers (data not shown). There was no correlation between I κ B expression and NF- κ B DNA binding activity in Hs578T and HBL-100 cells. Despite reduced levels of both I κ B α and I κ B β 2, NF- κ B DNA binding was intermediate in Hs 578T. It is possible that this cell line overexpresses other I κ B proteins. HBL-100 cells displayed elevated NF- κ B DNA binding activity despite the presence of I κ B α and I κ B β 2. Whether elevated NF- κ B DNA binding in this cell line is due to 1:1 ratio of I κ B β 1 and I κ B β 2 or due to reduced levels of other I κ B proteins is not known. Constitutive

NF- κ B DNA binding activity did not correlate with elevated levels of RelA and p50 proteins (Fig. 1B).

The Effect of I κ B α and I κ B β 1 Overexpression on Constitutive NF- κ B DNA Activity in MDA-MB-231 Cells—To determine the role of I κ B α and I κ B β in constitutive NF- κ B activation, we generated MDA-MB-231 cells overexpressing I κ B α and I κ B β 1. The levels of I κ B α and I κ B β 1 in cells transduced with empty retrovirus (LxSN3), I κ B α coding retrovirus (I κ B α 3-7), and I κ B β 1 containing retrovirus (I κ B β 21-25) were determined by Western blotting (Fig. 2A). Two clones containing vector alone (called LxSN3 and LxSN5 cells hereafter), two clones with I κ B α (I κ B α 5 and I κ B α 7 cells), and three clones with I κ B β 1 (I κ B β 21, I κ B β 22, and I κ B β 23) were chosen arbitrarily for this study. NF- κ B DNA binding activity in these clones is shown in Fig. 2B. I κ B α overexpression resulted in reduced constitutive DNA binding (compare lane 1 and 2 with lanes 3 and 4). Unexpectedly, constitutive NF- κ B DNA binding was the same in I κ B β cells and LxSN cells (compare lanes 1 and 2 with lanes 5-7). Similar results were obtained when nuclear extracts instead of whole cell extracts were used (Fig. 2B, lanes 8-14). Also, a similar binding pattern was obtained with PRDII element (NF- κ B-binding site in the interferon- β gene promoter which is flanked by the HMG I protein-binding site) and the NF- κ B-binding site of urokinase plasminogen activator (uPA) promoter (data not shown). The DNA-NF- κ B complex is a heterodimer of p50 and RelA as antibodies against both proteins supershifted the complex (data not shown). I κ B α or I κ B β overexpression did not affect DNA binding of AP-1 (Fig. 2B, lower panel).

As stated earlier, the hypophosphorylated I κ B β 1 enters the nucleus and forms a stable complex with DNA-bound NF- κ B. Inability of I κ B β 1 to reduce NF- κ B DNA binding activity could be due to unimpaired interaction of the I κ B β 1-NF- κ B complex with DNA. To address this possibility, we performed DNA immunoprecipitation assays with nuclear extracts from LxSN3, I κ B α 5, and I κ B β 21 cells. Radiolabeled DNA-NF- κ B complexes were immunoprecipitated with either RelA antibody, I κ B α antibody, or I κ B β antibody. Antibody against *neu* oncogene was used as a negative control. DNA-NF- κ B complex was efficiently immunoprecipitated by RelA antibody (Fig. 2C, lanes 1, 5, and 9). The amount of DNA-NF- κ B complex immunoprecipitated by RelA antibody was similar to the amount of NF- κ B-DNA complex identified in EMSA. Neither I κ B α antibody nor *neu* antibody immunoprecipitated DNA-NF- κ B complex from nuclear extracts (lanes 2, 4, 6, 8, 10, and 12). I κ B β antibody immunoprecipitated radiolabeled probe from only I κ B β 21 cells (compare lanes 3, 7, and 11). These results indicate that I κ B β 1 either binds directly to the NF- κ B-binding site or forms a stable complex with DNA-bound NF- κ B. Whatever the mechanism involved, DNA binding of I κ B β 1 did not interfere in DNA-NF- κ B interaction. I κ B β 1-DNA interaction was




FIG. 2. Overexpression of hI κ B α and mI κ B β 1 in MDA-MB-231 cells. *A*, I κ B α and I κ B β 1 in transduced clones. Whole cell extracts from individual G418-resistant clones of MDA-MB-231 cells were subjected to Western blotting using indicated antibodies. *B*, NF- κ B DNA binding activity in I κ B α - and I κ B β 1-overexpressing cells. Whole cell extracts (6 μ g, lanes 1–7) or nuclear extracts (10 μ g, lanes 8–14) from vector alone (LxSN3 and LxSN5), I κ B α -overexpressing (I κ B α 5 and I κ B α 7), or I κ B β 1-overexpressing (I κ B β 21, I κ B β 22, and I κ B β 23) cells were subjected to EMSA with either NF- κ B probe (top panel) or AP-1 probe (bottom panel). *C*, I κ B β 1 is associated with NF- κ B-binding site containing probe. An EMSA reaction with radiolabeled NF- κ B probe was performed with 15 μ g of nuclear extracts from indicated clones. EMSA reactions were subjected to immunoprecipitation using indicated antibodies. Antibodies against RelA and neu served as positive and negative controls, respectively. The amount of radioactive probe precipitated by RelA antibody from LxSN3 cells was set as 100%, and the relative difference is indicated.

not observed in antibody supershift assays possibly due to the unstable nature of the complex under electrophoresis conditions (data not shown).

Inducible DNA Binding of NF- κ B in Cells Overexpressing I κ B α and I κ B β —To investigate the effect of I κ B α and I κ B β on inducible DNA binding of NF- κ B, we performed EMSA with extracts from cells treated with either TPA or IL-1 β for 1 h. Inducible NF- κ B DNA binding activity was lower in I κ B α cells compared with other cells (Fig. 3A). As with constitutive DNA binding, I κ B β failed to inhibit inducible NF- κ B DNA binding. In fact, we consistently observed higher DNA binding in TPA-treated I κ B β cells compared with other cells (compare lanes 2,

5, 14, 17, and 20). I κ B α and I κ B β overexpression did not affect DNA binding of AP-1 (Fig. 3A, lower panel).

To determine whether I κ B α and I κ B β overexpression alters the time course of NF- κ B activation, EMSA was performed with the extracts from cells treated with TPA and IL-1 for specific intervals. TPA-inducible DNA binding activity was observed after 60 min of stimulation in all three cell types (Fig. 3B, compare lanes 4, 13, and 22) and started to decline after 3 h of stimulation. We consistently observed increased NF- κ B DNA binding activity in TPA-treated I κ B β cells compared with other cells. There was no cell type-specific variation in the rate of I κ B α degradation. Approximately 50% of I κ B α was present at 60 min and 2 h after TPA addition, and its level increased at 3 h (Fig. 3B). NF- κ B DNA binding activity at 6, 9, and 24 h after TPA addition was higher than in untreated cells which correlated with reduced levels of I κ B α . Degradation of I κ B β 1 was minimal (<25%) which was evident at 2 and 3 h post-stimulation. We next examined the time course of IL-1-induced NF- κ B DNA binding activity (Fig. 3C). NF- κ B DNA binding increased within 30 min of IL-1 addition in all three cell types. There was a difference in the termination of inducible DNA binding. In LxSN5 and I κ B α 5 cells, maximum DNA binding was observed after 1 h of IL-1 addition and returned almost to basal levels by 2 h. In contrast, in I κ B β 21 cells, a substantial level of inducible DNA binding persisted after 2 h of IL-1 addition. Similar results were obtained with three other I κ B β -overexpressing clones (data not shown). As with TPA-treated cells, I κ B α degradation occurred at a similar rate in all three cell types, and partial degradation of I κ B β (<30%) coincided with induction of NF- κ B DNA binding in I κ B β 21 cells (data not shown). Taken together, our results demonstrate that although I κ B α did inhibit constitutive DNA binding, neither I κ B α nor I κ B β 1 had much effect on inducible DNA binding of NF- κ B in MDA-MB-231 cells.

Activity of NF- κ B- and AP-1-dependent Promoters in I κ B α - and I κ B β 1-overexpressing Cells—The inability of I κ B β 1 to repress constitutive DNA binding of NF- κ B was unexpected. However, it is possible that I κ B β 1 may convert the NF- κ B-DNA complex to a transcriptionally inactive complex similar to retinoblastoma protein-induced inactivation of the NF- κ B-DNA complex (38). To address this possibility, we performed transient transfection experiments using an NF- κ B-dependent CAT reporter gene (NF- κ B/CAT, see Ref. 27). Expectedly, constitutive and inducible activities of the NF- κ B/CAT were lower in I κ B α cells compared with LxSN cells (Fig. 4A). Interestingly, inducible activities of NF- κ B/CAT, particularly with IL-1, were lower in I κ B β cells. The NF- κ B/CAT reporter gene expression requires the binding site for NF- κ B because a similar reporter in which the NF- κ B-binding site has been mutated is inactive in MDA-MB-231 cells (27).

As stated in the Introduction, NF- κ B interacts with AP-1, and this interaction results in synergistic activation of transcription. Because I κ B β 1 inhibited NF- κ B-dependent gene expression despite efficient DNA binding, it is possible that I κ B β 1 in the NF- κ B-DNA complex prevents synergistic interaction with AP-1 either due to a conformational change or steric hindrance. We measured constitutive and TPA-inducible activity of AP-1/CAT reporter gene in all cell lines. Similar levels of constitutive and TPA-inducible activity were observed in LxSN5, I κ B α 5, and I κ B α 7 cells (Fig. 4B). Due to differences in cell passage number, we consistently observed lower constitutive and TPA-inducible activities in LxSN3 cells. These cells were passed \sim 15 more times than other clones. For unknown reasons, decreasing levels of AP-1 transcriptional activation with increasing cell passage were consistently observed with this cell line. The constitutive and TPA-inducible activities of




FIG. 3. Inducible DNA binding of NF- κ B in I κ B-overexpressing cells. *A*, TPA- and IL-1 β -inducible DNA binding activity. Whole cell extracts from untreated (-), TPA-treated (125 nM), or IL-1 β -treated (2.5 ng/ml) cells were subjected to EMSA with either NF- κ B probe (*top panel*) or AP-1 probe (*bottom panel*). *B*, time course of TPA-inducible NF- κ B DNA binding activity. Whole cell extracts were prepared at specific intervals after treatment with TPA and subjected to EMSA (*top panel*). I κ B α in all cell types and I κ B β 1 in I κ B β 21 cells were analyzed by Western blotting. Western blot with LxSN5 cell extracts was exposed three times longer than other blots, and it was performed with double the amount of proteins. As a loading control, the same blots were reprobed with an antibody against α -tubulin. *C*, time course of IL-1-inducible NF- κ B DNA binding activity. The experiments were performed as in *B*.

AP-1 were reproducibly lower ($n = 6$) in I κ B β cells compared with other clones. Similar results were obtained with interleukin-11 (IL-11) promoter/CAT reporter with an AP-1-binding site (data not shown). The activity of the reporter gene is AP-1-dependent since an IL-11/CAT reporter in which the AP-1-binding site is mutated was inactive (data not shown). To confirm these results further, we performed transient transfection assays with AP-1/CAT reporter, RelA, and I κ B expression vectors in MDA-MB-231 cells. Because of a higher level of basal AP-1 activity, only a modest increase in AP-1/CAT activity in RelA-transfected cells was observed (Fig. 4C). Both I κ B α and I κ B β inhibited RelA-mediated increases in AP-1/CAT activity.

PEST Domain Mutants of I κ B β Inhibit NF- κ B Activity in MDA-MB-231 Cells—Recent studies have indicated that the hypophosphorylated form of I κ B β forms a stable complex with DNA-bound NF- κ B (14, 15, 29). Phosphorylation of Ser-313 and

Ser-315 of I κ B β by casein kinase II results in the release of both I κ B β and NF- κ B from DNA and, consequently, reduced transactivation in P19 and 293 cells (17, 29). Alternatively, promoter context-dependent interaction of HMG I with the I κ B β -NF- κ B-DNA complex results in the release of NF- κ B and I κ B β from DNA (17). Neither of the above two mechanisms appears to be responsible for reduced NF- κ B/CAT activity in I κ B β 1-overexpressing MDA-MB-231 cells because transactivation function but not the DNA binding of NF- κ B was inhibited by I κ B β 1 in these cells. To verify this further, we compared the ability of wild type and mutants of I κ B β (in which casein kinase II phosphorylation sites have been mutated to alanine or aspartic acid) to repress NF- κ B DNA binding activity in MDA-MB-231 and 293 cells. The effect of I κ B β 1 expression vector lacking 50 amino acids at the C terminus (mI κ B β 1 Δ C which lacks casein kinase II phosphorylation sites) on NF- κ B DNA




FIG. 4. Constitutive and inducible activity of NF- κ B- and AP-1-dependent promoters in I κ B-overexpressing clones. A, activity of NF- κ B-dependent promoter. NF- κ B/CAT reporter (5 μ g) was transfected along with an internal control plasmid coding for β -galactosidase into indicated cells. Cells were treated with either TPA (125 nM) or IL-1 β (2.5 ng/ml) 24 h after transfection. CAT activity in equal number of β -galactosidase units was measured 48 h after transfection. Constitutive NF- κ B/CAT activity in LxSN5 was set arbitrarily as 10 units, and the relative difference is shown. The mean and standard deviations from four experiments are shown. Basal, TPA- and IL-1-inducible NF- κ B activities were significantly lower in I κ B α - and I κ B β -overexpressing cells compared with LxSN cells ($p < 0.0005$). B, activity of AP-1-dependent promoter. AP-1/CAT (20 μ g) was transfected into indicated clones, and the CAT activity was measured as above. Basal and TPA-inducible AP-1 activities were significantly lower in I κ B β cells compared with other cells ($p < 0.0019$). □, untreated; ■, TPA; ▨, IL-1. C, RelA increases AP-1/CAT activity. MDA-MB-231 cells were transfected with 10 μ g of AP-1/CAT and indicated expression vectors. The amount of expression vector was kept constant in all transfections by substituting with the empty expression vector pCDNA3. Repression of RelA induced NF- κ B activity by I κ Bs was statistically significant ($p < 0.0018$) except in cells transfected with 0.5 μ g of I κ B α .

binding activity was also tested in parallel. Wild type but not the mutants of I κ B β 1 repressed NF- κ B DNA binding activity in 293 cells, which is consistent with previously published data (Fig. 5A). In contrast, both wild type and mutant I κ B β 1 failed to repress NF- κ B DNA binding in MDA-MB-231 cells. The C-terminal serines of I κ B β 1 appear to be phosphorylated in both cell types as the mutant proteins with either serine to alanine or serine to aspartic acid substitution displayed faster mobility than wild type I κ B β 1 on an SDS-polyacrylamide gel electrophoresis (Fig. 5A). We next compared the ability of wild type and mutant I κ B β 1 to repress transactivation function of NF- κ B in transient transfection assays. Mutants were as efficient as wild type I κ B β 1 in repressing NF- κ B activity (Fig. 5B). MDA-MB-231 cells stably expressing mI κ B β 1 Δ C were generated to confirm further these results (Fig. 5C). A new clone containing vector alone was also prepared so that all clones were of the same passage number. mI κ B β 1 Δ C overexpression did not affect constitutive NF- κ B DNA binding activity (Fig. 5C). As with the transient transfection assays, however, NF- κ B/CAT activity was reduced in clones overexpressing I κ B β 1 Δ C (Fig. 5D). Taken together, these results suggest that phosphorylation of I κ B β 1 by casein kinase II is not essential for repression of NF- κ B activity in MDA-MB-231 cells.

Serum and EGF-inducible Expression of uPA in I κ B α and I κ B β -overexpressing Cells—Multiple transcription factors including AP-1, NF- κ B, and the Ets are involved in constitutive and inducible expression of the uPA gene (39, 40). If the effect of I κ B β on NF- κ B- and AP-1-dependent gene expression observed in transient assays is relevant to endogenous gene expression, I κ B β overexpression should inhibit uPA gene expression. Serum and EGF were used as inducible agents as both can induce the activity of AP-1 and NF- κ B (41, 42). The basal expression level of uPA was consistently lower in LxSN3 compared with LxSN5, possibly due to the difference in passage number (Fig. 6). Both constitutive and inducible expression of uPA was reproducibly lower in I κ B α and I κ B β cells (Fig. 6, A and B). In general, the inducible expression was lower in I κ B β cells compared with I κ B α cells. Similar results were also obtained with cells overexpressing I κ B β 1 Δ C (Fig. 6C). The effect of EGF and serum on AP-1 and NF- κ B is mostly at the level of transactivation as DNA binding of both transcription factors was not significantly affected upon EGF and serum treatment (data not shown). These results further emphasize that I κ B β 1 can repress transcription without interfering with the DNA binding of NF- κ B in MDA-MB-231 cells.

uPA Expression in Breast Cancer Cell Lines—The above results indicate that NF- κ B plays an important role in uPA expression in breast cancer cells. To extend this observation further, we compared uPA expression with constitutive NF- κ B DNA binding activity in various breast cancer cell lines. uPA expression was observed only in cell lines that contained either intermediate or higher levels of constitutive NF- κ B activity (Fig. 7). Interestingly, uPA expression in three out of five cell lines correlated with reduced levels of I κ B β (MDA-MB-231, MDA-MB-436, and Hs578T). These results suggest that for optimum activation of NF- κ B-regulated genes, constitutive NF- κ B DNA binding should be accompanied by reduced levels of I κ B β 1.

DISCUSSION

Members of the Rel family of transcription factors are usually sequestered in the cytoplasm by I κ B proteins. Several recent studies have indicated that I κ B-mediated cytoplasmic retention of NF- κ B is altered during cancer progression. Although reduced levels of I κ B proteins may be responsible for nuclear NF- κ B in some cells, constitutive NF- κ B DNA binding has also been observed under conditions where I κ B α is abun-




FIG. 5. Inhibition of NF- κ B activity by PEST domain mutants of IκBβ1. *A*, effect of PEST domain mutants of IκBβ1 on DNA binding of NF- κ B in MDA-MB-231 and 293 cells. Cells (5×10^6) were transfected with 10 μ g of the indicated expression vectors. Whole cell extracts were prepared after 48 h of transfection and subjected to EMSA (*top panel*) and Western blotting (*bottom panel*). mIκBβ1 and mIκBβ1ΔC could not be detected in Western blots. Note the faster mobility of PEST domain mutants compared with wild type IκBβ1. *B*, PEST domain mutants of IκBβ1 are as efficient as wild type IκBβ1 in repressing NF- κ B-dependent promoter activity. MDA-MB-231 cells were transfected with the NF- κ B/CAT reporter gene (5 μ g) and an indicated expression vector. The amount of expression vector was kept constant in all transfections by substituting with the empty expression vector pcDNA3. CAT activity was measured 48 h after transfection. *C*, generation of stable MDA-MB-231 cells expressing mIκBβ1ΔC. Stable cell lines were generated by retrovirus-mediated gene transfer. The expression level of transduced gene and its effect on NF- κ B DNA binding activity were measured by Western blotting and EMSA, respectively. *D*, activity of NF- κ B/CAT in IκBβ1ΔC-expressing cells. Transfection and CAT assays were as in Fig. 4.

dant (24, 43). Tyrosine phosphorylation-mediated inactivation without degradation of IκB α or accumulation of hypophosphorylated IκB β which transports NF- κ B to the nucleus may account for constitutive NF- κ B DNA binding in cells with IκB α (15, 43). This study was initiated to understand the mechanisms of constitutive NF- κ B activation in breast cancer cells. Constitutive NF- κ B DNA binding was observed in cells that contained reduced level of IκB α (MDA-MB-435 and MDA-MB-

468), IκB β 2 (MDA-MB-436), or both IκB α and IκB β (MDA-MB-231). Expectedly, overexpression of IκB α could reverse constitutive NF- κ B DNA binding in MDA-MB-231 cells. However, it was unexpected that overexpressed IκBβ1 cannot inhibit NF- κ B DNA binding in MDA-MB-231 cells even though it could efficiently repress NF- κ B DNA binding in 293 cells (Fig. 5A, see also Ref. 29). The mechanisms responsible for the cell type-specific function of IκBβ1 is not known. Simeonidis *et al.* (44)




FIG. 6. Effect of IκB α and IκB β overexpression on uPA expression. *A*, serum-inducible expression of uPA. Total RNA (20 μ g) from indicated clones maintained in serum-free medium for 48 h (-) or treated for 4 h with 10% serum-containing media after serum starvation (+) was subjected to Northern blotting using a uPA probe. Integrity of the RNA was examined by reprobing the blot with ribosomal protein gene *36B4* (30). The ratio of autoradiograms was determined by densitometric scanning of autoradiograms. Results from a representative experiment are shown. *B*, EGF-inducible expression of uPA. Total RNA from untreated (-) or EGF-treated (30 ng/ml for 4 h) was subjected to Northern blotting as above. *C*, serum and EGF-inducible expression of uPA in cells overexpressing mIκB β 1 Δ C.

have shown that the strength by which different IκBs inhibit NF- κ B activity correlates with their ability to sequester NF- κ B in the cytoplasm rather than their ability to inhibit DNA binding of NF- κ B. They have also shown that the first three of six ankyrin repeats determine the cytoplasmic retention potential of IκBs, whereas the last three ankyrin repeats and the C-terminal PEST sequences determine the ability of IκBs to




FIG. 7. Expression of uPA in breast cancer cell lines. uPA expression was measured by Northern blotting.

inhibit DNA binding. IκB β 1 could neither prevent nuclear translocation nor prevent DNA binding of NF- κ B in MDA-MB-231 cells (Fig. 2 and Fig. 5). IκB β 1 was, however, able to inhibit transactivation by NF- κ B in these cells. Phosphorylation of PEST domain of IκB β 1 by casein kinase II (which is required for inhibition of DNA binding (16, 17)) is not necessary for repression of transactivation function of NF- κ B by IκB β 1 in MDA-MB-231 cells. We observed similar degrees of repression of NF- κ B activity by wild type and mutant IκB β 1 lacking casein kinase II phosphorylation sites (Fig. 5). These results suggest that IκB β 1 contains additional functional domains which only inhibit the transactivation function of NF- κ B. Detailed mutational analysis and domain swapping with other IκBs is essential for characterization of this domain. We have not directly tested whether this function of IκB β 1 is promoter context-dependent. In this regard, note that IκB β 1 reduced the expression of uPA and the transiently transfected reporter gene but failed to prevent the resynthesis of IκB α (which is dependent on NF- κ B) in cells treated with TPA (Fig. 3 and Fig. 6). Because the NF- κ B-binding site in the reporter gene and uPA gene lacks the binding sites for HMG I, the repression of NF- κ B activity is not likely due to the interaction of HMG I with NF- κ B-IκB β -DNA.

IκB β may inhibit transactivation by NF- κ B independent of its interaction with NF- κ B or through its association with DNA-bound NF- κ B. IκB β 1 may sequester a coactivator(s) which is essential for transactivation by NF- κ B. In this regard, proteins distinct from the IκB/NF- κ B family have been shown to interact with IκB β 1 (45, 46). IκB β 1 in the NF- κ B-DNA complex may inhibit transactivation in the following ways. (i) IκB β 1 may mask the region of RelA which undergoes a modification such as phosphorylation after DNA binding. Several recent studies have suggested that RelA phosphorylation is required for efficient transactivation. For example, Bergmann *et al.* (47) have demonstrated that inhibitors of phosphatidylcholine-specific phospholipase C and protein kinase C blocked transactivation by NF- κ B after TNF and IL-1 β treatment even though these inhibitors did not block nuclear translocation. Similarly, Yoza *et al.* (48) have demonstrated that activation of the protein-tyrosine kinase pathway is required for lipopolysaccharide-mediated NF- κ B activation but not nuclear translocation. Phosphorylation of RelA by kinases activated by TNF- α and *ras* oncogene has also been reported (49, 50). RelA appears to be the target of protein kinase A or casein kinase II following degradation of IκBs (51, 52). Protein kinase A-mediated phosphorylation by RelA is required for unmasking of intramolecular interaction sites and subsequent interaction of RelA with

coactivator p300/CBP (53). It is possible that phosphorylation by protein kinase A and other kinases and/or coactivator-NF- κ B interaction is inefficient when I κ B β 1 is present in the NF- κ B-DNA complex. (ii) I κ B β has been shown to interact with nuclear receptors including thyroid hormone receptors and retinoid-X receptors (45, 46). Because nuclear receptors such as estrogen receptor, progesterone receptors, and peroxisome proliferator receptors have been shown to inhibit NF- κ B activity, I κ B β 1 in the NF- κ B-DNA complex may recruit retinoid-X receptors: peroxisome proliferator receptor heterodimers to the NF- κ B-DNA complex and inhibit transactivation by NF- κ B (27, 54–56). (iii) I κ B β 1 may inhibit synergistic interaction of NF- κ B with other transcription factors including AP-1. We have provided some evidence for the last possibility. Synergistic cross-talk between NF- κ B and AP-1 is essential for anchorage-independent growth of immortalized keratinocytes (57). Inhibitors of both NF- κ B and AP-1 block tumor promoter-induced transfection (58), suggesting the importance of cross-talk in cancer progression. We suspect that such cross-talk is more pronounced in cancer cells lacking I κ B β 1. These cells will be more responsive to growth factors and serum. Consistent with this possibility, serum and EGF-inducible expression of uPA was more pronounced in cells lacking I κ B β 1. We have observed increased uPA expression in most of the breast cancer cell lines that contain constitutively active NF- κ B. uPA is absolutely required for intravasation, the most important step in the multistep process of tumor metastasis (59), and its overexpression in breast cancer cells is associated with poor prognosis (60). In summation, our results suggest that I κ B β regulates NF- κ B activity in a cell type-specific manner which determines whether constitutive DNA binding of NF- κ B leads to overexpression of NF- κ B-regulated genes such as uPA.

Acknowledgments—We thank D. W. Ballard, K. Cornetta, S. Ghosh, H. Goonewardena, W. C. Greene, E. O'Neill, and Y. C. Yang for various plasmids. We also thank E. M. Goheen for technical assistance.

REFERENCES

- Baeuerle, P. A., and Henkel, T. (1994) *Annu. Rev. Immunol.* **12**, 141–179
- Baeuerle, P. A., and Baltimore, D. (1996) *Cell* **87**, 13–20
- Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., and Miyamoto, S. (1995) *Genes Dev.* **9**, 2723–2735
- Whiteside, S. T., Epinat, J.-C., Rice, N. R., and Israel, A. (1997) *EMBO J.* **16**, 1413–1426
- Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. (1997) *Science* **275**, 523–527
- Na, S.-Y., Lee, S.-K., Han, S.-J., Choi, H.-S., Im, S.-Y., and Lee, J. W. (1998) *J. Biol. Chem.* **273**, 10831–10834
- Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., and Collins, T. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 2927–2932
- Kerr, L. D., Ransone, L. J., Wamsley, P., Schmitt, M. J., Boyer, T. G., Zhou, Q., Berk, A. J., and Verma, I. M. (1993) *Nature* **365**, 412–419
- Stein, B., Baldwin, A. S., Jr., Ballard, D. W., Greene, W. C., Angel, P., and Herrlich, P. (1993) *EMBO J.* **12**, 3879–3891
- Franzoso, G., Carlson, L., Brown, K., Daucher, M. B., Bressler, P., and Siebenlist, U. (1996) *EMBO J.* **15**, 3403–3412
- Thompson, J. E., Phillips, R. J., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1995) *Cell* **80**, 573–582
- Weil, R., Laurent-Winter, C., and Israel, A. (1997) *J. Biol. Chem.* **272**, 9942–9949
- Cheshire, J. L., and Baldwin, A. S., Jr. (1997) *Mol. Cell. Biol.* **17**, 6746–6754
- Chu, Z.-L., McKinsey, T. A., Liu, L., Qi, X., and Ballard, D. W. (1996) *Mol. Cell. Biol.* **16**, 5974–5984
- Suyang, H., Phillips, R., Douglas, I., and Ghosh, S. (1996) *Mol. Cell. Biol.* **16**, 5444–5449
- Phillips, R. J., and Ghosh, S. (1997) *Mol. Cell. Biol.* **17**, 4390–4396
- Tran, K., Merika, M., and Thanos, D. (1997) *Mol. Cell. Biol.* **17**, 5386–5399
- Hirano, F., Chung, M., Tanaka, H., Maruyama, N., Makino, I., Moore, D., and Scheidereit, D. (1998) *Mol. Cell. Biol.* **18**, 2596–2607
- Simeonidis, S., Liang, S., Chen, G., and Thanos, D. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 14372–14377
- Gilmore, T. D., Koedood, M., Piffat, K. A., and White, D. W. (1996) *Oncogene* **13**, 1367–1378
- Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. (1998) *Science* **281**, 1680–1683
- Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dorken, B. (1997) *J. Clin. Invest.* **100**, 2961–2969
- Shattuck-Brandt, R., and Richmond, A. (1997) *Cancer Res.* **57**, 3032–3039
- Giri, D. K., and Aggarwal, B. B. (1998) *J. Biol. Chem.* **273**, 14008–14014
- Yamaoka, S., Inoue, H., Sakurai, M., Sugiyama, T., Hazama, M., Yamada, T., and Hatanaka, M. (1996) *EMBO J.* **15**, 873–877
- Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., and Baldwin, A. S., Jr. (1998) *Genes Dev.* **12**, 968–981
- Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., and Sledge, G. W., Jr. (1997) *Mol. Cell. Biol.* **17**, 3629–3639
- Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., and Sonenshein, G. E. (1997) *J. Clin. Invest.* **100**, 2952–2960
- McKinsey, T. A., Chu, Z.-L., and Ballard, D. W. (1997) *J. Biol. Chem.* **272**, 22377–22380
- Bhat-Nakshatri, P., Newton, T., Goulet, R., Jr., and Nakshatri, H. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 6971–6976
- Lee, W., Mitchell, P., and Tjian, R. (1987) *Cell* **49**, 741–752
- Miller, A. D., and Rosman, G. J. (1989) *BioTechniques* **7**, 980–990
- Markowitz, D., Goff, S., and Bank, A. (1988) *J. Virol.* **62**, 1120–1124
- Cornetta, K., Moore, A., Johannesson, M., and Sledge, G. W. (1994) *Clin. Exp. Metastasis* **12**, 3–12
- Harlow, E., and Lane, D. (1988) *Antibodies: A Laboratory Manual*, pp. 421–470, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) *Nucleic Acids Res.* **11**, 1475–1489
- Sommers, C. L., Byers, S. W., Thompson, E. W., Torri, J. A., and Gelmann, E. P. (1994) *Breast Cancer Res. Treat.* **31**, 325–335
- Tamami, M., Lindholm, P. F., and Brady, J. N. (1996) *J. Biol. Chem.* **271**, 24551–24556
- Hansen, S. K., Nerlov, C., Zabel, U., Verde, P., Johnsen, P. A., Baeuerle, P. A., and Blasi, F. (1992) *EMBO J.* **11**, 205–213
- Nerlov, C., Rorth, P., Blasi, F., and Johnsen, M. (1991) *Oncogene* **6**, 1583–1592
- Hill, C. S., and Treisman, R. (1995) *Cell* **80**, 199–211
- Sun, L., and Carpenter, G. (1998) *Oncogene* **16**, 2095–2102
- Imbert, V., Rupec, R. A., Livolsi, A., Pahl, H. L., Traenckner, E. B., Mueller Dieckmann, C., Farahifar, D., Rossi, R., Auberger, P., Baeuerle, P. A., and Peyron, J.-F. (1996) *Cell* **86**, 787–798
- Simeonidis, S., Stauber, D., Chen, G., Hendrickson, W. A., and Thanos, D. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 49–54
- Na, S.-Y., Kim, H.-J., Lee, S.-K., Choi, H.-S., Na, D.-S., Lee, M.-O., Chung, M., Moore, D. D., and Lees, J. W. (1998) *J. Biol. Chem.* **273**, 3212–3215
- Lee, J. W., Choi, H.-S., Gyurist, J., Brent, R., and Moore, D. D. (1995) *Mol. Endocrinol.* **9**, 243–254
- Bergmann, M., Hart, L., Lindsay, M., Barnes, P. J., and Newton, R. (1998) *J. Biol. Chem.* **273**, 6607–6610
- Yoza, B. K., Hu, J. Y. Q., and McCall, C. E. (1996) *J. Biol. Chem.* **271**, 18306–18309
- Finco, T. S., Westwick, J. K., Norris, J. L., Beg, A. A., Der, C. J., and Baldwin, A. S., Jr. (1997) *J. Biol. Chem.* **272**, 24113–24116
- Wang, D., and Baldwin, A. S., Jr. (1998) *J. Biol. Chem.* **273**, 29411–29416
- Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997) *Cell* **89**, 413–424
- Bird, T. A., Schooley, K., Dower, S. K., Hagen, H., and Virca, G. D. (1997) *J. Biol. Chem.* **272**, 32606–32612
- Zhong, H., Voll, R. E., and Ghosh, S. (1998) *Mol. Cell* **1**, 661–671
- Stein, B., and Yang, M. X. (1995) *Mol. Cell. Biol.* **15**, 4971–4979
- Kalkhoven, E., Wissink, S., van der Saag, P. T., van der Burg, B. (1996) *J. Biol. Chem.* **271**, 6217–6224
- Ricote, M., Li, A. C., Wilson, T. M., Kelly, C. J., and Glass, C. K. (1998) *Nature* **391**, 79–82
- Li, J.-J., Rhim, J. S., Schlegel, R., Vousden, K. H., and Colburn, N. H. (1998) *Oncogene* **16**, 2711–2721
- Li, J.-J., Westergaard, C., Ghosh, P., and Colburn, N. H. (1997) *Cancer Res.* **57**, 3569–3576
- Kim, J., Yu, W., Kovalski, K., and Ossowski, L. (1998) *Cell* **94**, 353–362
- Duffy, M. J., O'Grady, P., Devaney, D., O'siornain, L., Fennelly, J. J., and Lijnen, H. J. (1988) *Cancer (Phila.)* **62**, 531–533

Negative Regulation of Transactivation Function but Not DNA Binding of NF- κ B and AP-1 by I κ B β 1 in Breast Cancer Cells

Thomas R. Newton, Nikhil M. Patel, Poornima Bhat-Nakshatri, Carmen R. Stauss, Robert J. Goulet, Jr. and Harikrishna Nakshatri

J. Biol. Chem. 1999, 274:18827-18835.
doi: 10.1074/jbc.274.26.18827

Access the most updated version of this article at <http://www.jbc.org/content/274/26/18827>

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 59 references, 33 of which can be accessed free at <http://www.jbc.org/content/274/26/18827.full.html#ref-list-1>